Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis

被引:7
作者
Garcia Hernandez, Francisco Jose [1 ]
Castillo Palma, Maria Jesus [1 ]
Montero Mateos, Enrique [1 ]
Gonzalez Leon, Rocio [1 ]
Lopez Haldon, Jose Eduardo [2 ]
Sanchez Roman, Julio [1 ]
机构
[1] Hosp Univ Virgen del Rocio, Serv Med Interna, Seville, Spain
[2] Hosp Univ Virgen del Rocio, Serv Cardiol, Seville, Spain
来源
MEDICINA CLINICA | 2016年 / 146卷 / 01期
关键词
Systemic sclerosis; Pulmonary hypertension; Screening; CONNECTIVE-TISSUE DISEASE; ARTERIAL-HYPERTENSION; PREVALENCE; SURVIVAL; ECHOCARDIOGRAPHY; MULTICENTER; SCLERODERMA; EXERCISE; REGISTRY;
D O I
10.1016/j.medcli.2015.04.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: Pulmonary arterial hypertension (PAH) is an important cause of morbimortality in systemic sclerosis (SSc). Evolution is worse than that of subjects with idiopathic PAH, but prognosis improves when PAH is diagnosed early. The aim of this research is to describe results of a screening program for diagnosis of pulmonary hypertension (PH) carried out in a cohort of Spanish patients with SSc. Patients and method: PH screening was performed by transthoracic doppler echocardiography (TTDE) in 184 patients with SSc. Patients with systolic pulmonary arterial pressure estimated by TTDE >35 mmHg were evaluated per protocol to confirm diagnosis and type of PH. Results: PAH was diagnosed in 25 patients (13.6%). Patients with diffuse and limited SSc developed PAH in a similar degree, 9/60 (15%) vs. 16/100 (16%), with no cases among patients with SSc "sine scleroderma" or "pre-scleroderma" (P < .001). The only clinical or epidemiological data characterizing patients with PAH were older age (mean age 67 years for patients with PAH vs. 56 years for those without PAH, P =. 007), limited SSc, a trend toward shorter evolution of the underlying disease (median 8 years for patients with PAH vs. 10 years for those without PAH, P = .73), and a higher frequency of positive anticentromere antibodies (16 patients [64%] with PAH vs. 70 (48,3%) without PAH, P = .19). Conclusions: Prevalence of PAH in SSc was high and supports the implementation of a regular screening program. (C) 2015 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 32 条
[11]   Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study [J].
Hsu, Vivien M. ;
Chung, Lorinda ;
Hummers, Laura K. ;
Wigley, Fredrick ;
Simms, Robert ;
Bolster, Marcy ;
Silver, Rick ;
Fischer, Aryeh ;
Hinchcliff, Monique E. ;
Varga, John ;
Goldberg, Avram Z. ;
Derk, Chris T. ;
Schiopu, Elena ;
Khanna, Dinesh ;
Shapiro, Lee S. ;
Domsic, Robyn T. ;
Medsger, Thomas ;
Mayes, Maureen D. ;
Furst, Daniel ;
Csuka, Mary E. ;
Molitor, Jerry A. ;
Alkassab, Firas ;
Steen, Virginia D. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 44 (01) :55-62
[12]   Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis [J].
Kawut, SM ;
Taichman, DB ;
Archer-Chicko, CL ;
Palevsky, HI ;
Kimmel, SE .
CHEST, 2003, 123 (02) :344-350
[13]  
Koh ET, 1996, BRIT J RHEUMATOL, V35, P989
[14]   Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review [J].
Kovacs, G. ;
Berghold, A. ;
Scheidl, S. ;
Olschewski, H. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (04) :888-894
[15]   Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol [J].
Kuhn, KP ;
Byrne, DW ;
Arbogast, PG ;
Doyle, TP ;
Loyd, JE ;
Robbins, IM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (04) :580-586
[16]   Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival [J].
MacGregor, AJ ;
Canavan, R ;
Knight, C ;
Denton, CP ;
Davar, J ;
Coghlan, J ;
Black, CM .
RHEUMATOLOGY, 2001, 40 (04) :453-459
[17]   Prognosis of pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].
McLaughlin, VV ;
Presberg, KW ;
Doyle, RL ;
Abman, SH ;
McCrory, DC ;
Fortin, T ;
Ahearn, G .
CHEST, 2004, 126 (01) :78S-92S
[18]   Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach [J].
Mukerjee, D ;
St George, D ;
Coleiro, B ;
Knight, C ;
Denton, CP ;
Davar, J ;
Black, CM ;
Coghlan, JG .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) :1088-1093
[19]   Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease [J].
Oudiz, RJ ;
Schilz, RJ ;
Barst, RJ ;
Galié, N ;
Rich, S ;
Rubin, LJ ;
Simonneau, G .
CHEST, 2004, 126 (02) :420-427
[20]   Pulmonary artery hypertension as the presenting feature of systemic sclerosis sine scleroderma [J].
Pauling, J. D. ;
Gunawardena, H. ;
Coghlan, J. G. ;
Easaw, J. ;
Suntharalingam, J. ;
McHugh, N. J. .
RHEUMATOLOGY, 2008, 47 (09) :1431-1432